Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marizomib for Recurrent Ependymoma
NCT03727841Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of marizomib in ependymoma, sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival at 6 Months. Started Jan 2020; status: terminated.
02
Drugs
marizomib
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT03727841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727841.